ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Servier terminates CTI cancer pact following clinical failure
February 28, 2019Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial.... -
CTI, Servier’s Pixuvri fails in post-marketing trial
July 16, 2018A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy. -
Servier opens Kendall Square site, plans Chinese office to access external innovation
June 11, 2018Servier has opened a site in Kendall Square and staffed it with people from Biogen and the University of Massachusetts to find R&D and licensing opportunities. -
Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractor
March 13, 2017Servier, together with Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S.
Pharma Sources Insight January 2025
